OrthAlign exceeded total 2014 sales forecasts.
"OrthAlign's precision alignment technology continues to gain recognition and grow in the global marketplace, as more and more surgeons are seeing value in its accuracy and simplicity," said CEO William E. Maya. "2014's key highlights were exceeding sales forecasts, the rapid market penetration we are seeing internationally, receiving FDA clearance for our soon-to-be released hip technology OrthAlign Plus and the stamp of approval that we received from River Cities Capital Funds and Mutual Capital Partners Funds with the completion of a $15 million capital raise in November."
Here are five things to know about the report:
1. OrthAlign grew by more than 46 percent from 2013 to 2014.
2. The company's KneeAlign total Knee Arthroplasty reached 25,000 cases.
3. OrthAlign is continuing to position itself to build on 2014 momentum this year and continue expansion.
4. The KneeAlign provides precise tibial and femoral alignment technology and is compatible with all implant systems.
5. Alignment in TKA with Knee Align compares favorably to large-console computer-assisted surgery systems.